Targeted Oncology2h
Post-Operative Nivolumab Significantly Improves DFS in Head and Neck Cancer
Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development ...
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...
Barinthus Biotherapeutics: Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identifiedExten ...
Targeted Oncology18h
Reviewing the Options for Bladder Cancer in Different Settings
Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...
Personalized Medicine Biomarkers Market To Grow To USD 58.39 Billion By 2032, Driven By Precision Medicine Innovations
Rising Demand for Targeted Therapies and Advancements in Genomic Technologies Propel the Personalized Medicine Biomarkers market to a 14.54% CAGR Akash Anand SNS Insider Pvt. Ltd 415-230-0044 email us ...